Eli Lilly's ceperognastat, an O-GlcNAcase inhibitor, slowed brain atrophy and tau accumulation in a Phase 2 trial for early symptomatic Alzheimer's disease.
Eisai's E2814, an anti-tau drug, showed promise in reducing disease biomarkers in a Phase 1 trial involving participants with genetic Alzheimer's, warranting further studies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.